Dermata Therapeutics, Inc. (DRMA) shares climbed Wednesday after the biotech company announced it's raising money through a private placement that could bring in some much-needed cash for its upcoming product launches.
The company has entered into definitive agreements for a private placement offering worth approximately $12.4 million. Here's what investors are getting: 2,022,062 common shares (or pre-funded warrants for those who prefer that structure), Series C warrants, and short-term Series D warrants. Everything is priced at $2.04 per share, following Nasdaq's at-the-market rules.
The warrants come with some strings attached. They'll only become exercisable once stockholders give their approval, and they have different expiration timelines. Series C warrants expire in five years, while the short-term Series D warrants have a 24-month window.
The offering is expected to close around December 29, 2025. Notably, company insiders are putting their own money in at the same terms as everyone else, which often signals management confidence in the deal.
Following the Money
Dermata expects to raise approximately $4.1 million in gross proceeds from the initial offering, before deducting placement agent fees and other expenses. That's the guaranteed money walking in the door.
But there's potentially more on the horizon. If warrant holders decide to exercise their Series C and Series D warrants down the line, that could generate an additional $8.3 million. Of course, there's no guarantee anyone will exercise these warrants, especially if the stock doesn't perform well.
The company has laid out its spending plans pretty clearly. The net proceeds will go toward general corporate purposes, including consumer research, pre-launch and launch activities for its over-the-counter acne kit, potential investments in or acquisitions of complementary or emerging technology companies, licensing activities, and working capital to keep the lights on.
Sweetening the Deal for Earlier Investors
Dermata is also throwing a bone to some earlier warrant holders. The company agreed to amend certain outstanding warrants covering 120,734 shares of common stock that were originally issued on January 23, 2025. These warrants had an exercise price of $12.70 per share (adjusted for a one-for-10 reverse stock split that happened on July 30, 2025).
After the deal closes, those amended warrants will get a significantly reduced exercise price of $2.04 per share, matching the current offering. They'll also become exercisable upon stockholder approval and expire five years from that approval date.
For context, the company currently has 1,175,798 shares of common stock issued and outstanding, which means this offering will represent significant dilution for existing shareholders.
DRMA Price Action: Dermata Therapeutics shares were up 20.10% at $2.45 at the time of publication on Wednesday. The stock is trading near its 52-week low of $1.96.